

G1070-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant: Kenneth W. BATCHELOR**

**Serial No.: 08/405,120**

**Art Unit: 1202**

**Filed: March 16, 1995**

**Examiner: D. Daus**

**Allowed: May 23, 1996**

**Batch No.: A22**

**Title: ANDROSTENONE DERIVATIVE**

**Assistant Commissioner of Patents and Trademarks**

**Washington, D.C. 20231**

**Transmittal of Issue Fee PTO 85(b) and 85(c)  
With Certificate of Assignee's Name Change**

Sir:

Enclosed is payment of the Issue Fee PTO 85(b) for this application which was allowed **May 23, 1996**

Also enclosed is PTO 85(c) authorizing Examiner to charge any fee which might be due as a result of payment of the Issue Fee and for the order of 20 soft copies of the patent to issue, or to credit any overcharge, to applicant's **Deposit Account No. 07-1392.**

Also attached is a North Carolina Certificate of Name Change for Glaxo Inc. to Glaxo Wellcome Inc.

Respectfully submitted,

*Robert H. Brink*

Robert H. Brink  
Attorney of Record  
Registration No. 36,094

Date:

Glaxo Wellcome Inc.  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
(919) 483-6983

**CERTIFICATE OF MAILING (37 CFR 1.8a)**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addresses to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date: July 31, 1996

*Rosalie Germano*  
Rosalie Germano